PAREXEL and Osaka International Cancer Institute Form Alliance to Advance Clinical Research in Japan


Alliance to drive greater efficiencies across clinical trials in oncology and hematology

BOSTON and OSAKA, August 21, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Osaka International Cancer Institute today announced that they have formed an alliance to advance clinical development in Japan. The partnership will aim to drive greater efficiencies in support of patient recruitment for clinical trials in oncology and hematology, accelerating the development of innovative and effective new cancer treatments for patients.

“Oncology continues to be the largest therapeutic area in clinical trials today, and is a priority for PAREXEL as we partner with clients to deliver new therapies to patients in need,” said Shogo Nakamori, Corporate Vice President, Clinical Research Services, Asia Pacific, PAREXEL. “Osaka International Cancer Institute is a center of excellence for clinical trials in the Kansai region of Japan. Through this alliance, PAREXEL and the Osaka International Cancer Institute will work to drive greater efficiencies for local and global biopharmaceutical companies, helping them accelerate the clinical development of innovative and effective new treatments in this difficult disease area.”

“The advancement of clinical trials in oncology is imperative in the development of promising new therapies for patients in Japan and around the world,” said Dr. Nariaki Matsuura, President of Osaka International Cancer Institute. “We are pleased to be working with PAREXEL, an innovative partner with a large presence in Japan, and globally, with leading clinical and scientific expertise in oncology. Through this collaboration, Osaka International Cancer Institute will gain access to novel treatments sooner, providing a wider range of potential treatment options for our patients and allowing us to make a strong contribution to the further advancement of cancer treatments.”

PAREXEL established operations in Japan in 1995 and has more than 1,300 employees based in Tokyo, Kobe, and Osaka. PAREXEL is a leading provider of biopharmaceutical services in the Asia-Pacific region, helping clients design drug development programs and conduct studies regionally and internationally. Over the last five years alone, PAREXEL has led more than 2,300 oncology projects in over 1.2 million patients across nearly 78,000 sites worldwide.


About Osaka International Cancer Institute
The Osaka International Cancer Institute was established in September 1959 as the Osaka Prefectural Lifestyle Related Disease Center. In March 2017 it was renamed the Osaka International Cancer Institute and relocated to its current location. The Center consists of the hospital division, the research division, and the cancer control center. The hospital was the first public hospital in Japan to be certified as an advanced treatment hospital and retains this honor to date. Among the top hospitals in the country, the Osaka International Cancer Institute provides various treatment options, including surgery, chemotherapy, radiotherapy, and immunotherapy treatments. The hospital has a high level of technical expertise and experience in treating cancer, specializing in refractory cancers, such as pancreatic cancer. The research division has its own cancer cell processing/culture method, CTOS/iCC, for the development of new cancer treatments, and the cancer control center serves as an advisor on public policies for cancer control to Osaka Prefecture, leveraging cancer registry data. Together the three divisions provide education and treatment for patients with cancer.

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 86 locations in 51 countries around the world, and had approximately 19,370 employees in the third quarter. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

# # #

PAREXEL Contacts:

Media:
Minori Niso
Tel.: +81 3-5543-9500
Email: Minori.Niso@PAREXEL.com

Dana Robie
Tel.: +1 781-434-4772
Email: Dana.Robie@PAREXEL.com

Investors:
Ronald Aldridge
Tel.: +1 781-434-4753
Email: Ron.Aldridge@PAREXEL.com

Osaka International Cancer Institute Contact:
Hiroshi Yamasaki, Public Relations
Tel.: +81 6-6945-1181
Email: yamasakih@opho.jp

Have any Question or Comment?

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

::::::::::::::::::::::::::::::::::6733:::::::::::::::::::::::::::::::::;;

:::::::::::::::::::::::::::::925:::::::::::::::::::::::::::::::

TRIO STEEL IS ONE OF THE MOST TRUSTED BRAND AND LEADING EXPORTER AND SUPPLIER OF CARBON STEEL, ALLOY STEEL & STAINLESS STEEL PIPES & PIPE FITTINGS MATERIAL. Triosteel is one of the leading Suppliers and Exporters of API 5L Pipe in Singapore. Triosteel also Exports to many countries like Indonesia, Iran, Saudi Arabia & many more. An API 5L pipe is manufactured by adhering to the specifications laid down by the International Organization for Standardization (ISO) 3183.

2780

buy! buy! CHEAP! Telefonie VoIP CHEAP! buy! buy! CHEAP!

2781

buy! buy! CHEAP! Telefonie VoIP CHEAP! buy! buy! CHEAP!

——————————————–

For the 2012 MLB period, we found an totals forecast Joao’s Renowned Over/Under João Zorro Gonçalves, Zcode Totals Pro, System of the time with progressions that have been successful over 98 98% ... We eventually perfected our over/under program ( Zcodesystemexclusive ), although it h-AS has brought years of investigation. Five Steps to Making a Winning MLB Method: 1. Execute appropriate cash management tools. 2. MLB rules that are comprehend. 3.Extensive testing back to make sure successful longterm results ...

——————————————–

There is always a challenge when you're dealing with the Foreign Exchange Market. That's just the nature of the beast. The best thing you can do is to learn about how the market operates as a whole so that you will be ready to meet these challenges. iq option penipu Never be misled by any profit gains in binary options. This is the number-one way traders end up losing their money and ultimately failing. Remember that the same things that make you laugh can make you cry in this market, and you can lose that $700.

——————————————–

Learning Polish has never been this fun and easy as with our podcasts Learn Polish with Polishpod101 Start today and become conversational in Polish in no time

——————————————–

The Best Website Agen Poker Resmi www.sakupoker.com Terpercaya come join

——————————————–

Do you need edmonton phone systems service ? Call complete communications today!

——————————————–

High-tech solutions for easy start-up of your IPTV/OTT-business

——————————————–

——————————————–

If you want to purchase not only one item, you have a chance to enjoy privileges. There is a sale’ tab on the site which offers a fantastic range of reduced counterfeit watches and accessories, such as sunglasses, cufflinks, watch straps and pens. Luxury Jewelry Replica At MCA.MN On Sale You get a 5% discount if you buy two pieces, this discount increases to 10% if you buy 4 pieces or more. There is free international shipping on all orders on this site. We also offer customers a free return anytime with a 100% money back guarantee.

——————————————–